Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Kwok Chi Lam"'
Autor:
Amy T.Y. Chang, Tony Mok, Frankie Mo, Jacky Y.C. Li, Oscar S.H. Chan, Ki Wang, Catherine Y.H. Wong, Rebecca M.W. Yeung, Kwok Chi Lam, Frankie P. T. Choi
Publikováno v:
Lung Cancer. 142:41-46
Objectives NSCLC patients harboring EGFR mutation invariably developed resistance to EGFR TKI. We postulated that oligoresidual disease (ORD) after initial TKI might harbor resistant clones. This study aimed to test if preemptive local ablative thera
Autor:
Hai-Yan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Kai Li, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, B. J. Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Yahui Tian, Zhiyi Xue, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou, Yi-Long Wu
Publikováno v:
Targeted Oncology
Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clini
Autor:
Martin Schuler, Kwok Chi Lam, Abdul Rahman Jazieh, Maximilian Hochmair, Chun-Ming Tsai, Gerd Stehle, Nicole D Forman, Agnieszka Cseh, Wolfgang Hilbe, S. Linden, Ross A. Soo, Robert M. Lorence, Federico Cappuzzo
Aim: A global afatinib named patient use program in non-small-cell lung carcinoma (NSCLC) commenced in 2010. Materials & methods: Eligible NSCLC patients had progressed after clinical benefit on prior erlotinib/gefitinib and/or had activating EGFR/HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e317ca6fef596c1488f33068cd86d111
https://www.ncbi.nlm.nih.gov/pubmed/29376400
https://www.ncbi.nlm.nih.gov/pubmed/29376400
Publikováno v:
Thoracic cancer. 4(1)
There is no consensus on the best management of symptomatic malignant pleural effusion. Drainage with a small bore pleural catheter is preferred over a wide bore catheter or recurrent pleural aspiration in patients with symptomatic malignant pleural
Autor:
C. Wong, Frankie P. T. Choi, F. Mo, Rebecca M.W. Yeung, Ki Wang, Tony Mok, Kwok Chi Lam, O.S.h. Chan, Amy T.Y. Chang, Jacky Y.C. Li
Publikováno v:
Journal of Thoracic Oncology. 13:S336
Publikováno v:
Journal of Clinical Oncology. 31:1081-1088
First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. Six randomized studies have demonstrated consistent improvement in tumor response rate and progressi
Publikováno v:
Thoracic Cancer. 4:9-13
There is no consensus on the best management of symptomatic malignant pleural effusion. Drainage with a small bore pleural catheter is preferred over a wide bore catheter or recurrent pleural aspiration in patients with symptomatic malignant pleural
Autor:
Kwok Chi Lam, Tony Mok
Publikováno v:
Respirology. 16:13-21
Lung cancer remains one of the most fatal illnesses. Recent development in cancer genomics and molecular targeted therapy leads to a paradigm shift in management of advanced-stage non-small cell lung cancer. Patients with activated mutation of epider
Autor:
Annette Poon, Frankie Kf Mo, Jane Koh, Winnie Yeo, Wing M. Ho, W. K. Yeung, Wan Yee Lau, Tony Mok, Stephen L. Chan, Edwin P. Hui, Kenneth K.C. Lee, Kwok Chi Lam, Joyce J. S. Suen, Benny Zee, Wing Hong Kwan
Publikováno v:
Breast Cancer Research and Treatment. 113:529-535
Objectives This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients. The primary objective was to compare the efficacy of aprepitant-based anti
Autor:
Anthony P.C. Yim, Herman Wong, Gong Chan, Wing M. Ho, Winnie Yeo, Yolanda Y. P. Lee, Kwok Chi Lam, Simon S. M. Ho, Anthony T.C. Chan, Karen Chak, Tony Mok
Publikováno v:
Journal of Thoracic Oncology. 2:838-844
Background Sequential administration of platinum-based doublet therapy and then a taxane may reduce the risk of drug resistance and, therefore, improve treatment outcome. This study was designed to evaluate the efficacy and tolerability of sequential